Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIa Clinical Trial With Dose Escalation to Evaluate Safety and Efficacy of the Infusion of CART84 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).

NCT07471789 is registered in ClinicalTrials.gov with Gyala Therapeutics as lead sponsor.

NCT NCT07471789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07471789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIa Clinical Trial With Dose Escalation to Evaluate Safety and Efficacy of the Infusion of CART84 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
Lead sponsor
Gyala Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 4, 2026
Completion date
February 4, 2031
Enrollment
33 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloblastic leukaemia, leukemia, t-cell